Journal of Clinical Oncology
Articles in this Issue
IDeate-Prostate01: A phase 3, randomized, open-label study of ifinatamab deruxtecan versus docetaxel in participants with previously treated metastatic castration-resistant prostate cancer.
TPS294 Background: Standard treatments for metastatic castration-resistant prostate cancer (mCRPC) include androgen depriv...
OMAHA-003: Phase 3 trial of CYP11A1 inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants (pts) with metastatic castration-resistant prostate cancer (mCRPC) after ARPI and taxane-based chemotherapy.
TPS298 Background: The androgen receptor (AR) plays a pivotal role in prostate cancer pathogenesis, even after progression...
Harnessing caregiver support to improve shared decision-making in metastatic prostate cancer treatment: A US-based quantitative survey.
131 Background: Caregivers play a pivotal role for many patients with prostate cancer (PC), providing emotional and physic...
[ <sup>177</sup> Lu]Lu-PSMA-617 ( <sup>177</sup> Lu-PSMA-617) in combination with an androgen receptor pathway inhibitor (ARPI) versus <sup>177</sup> Lu-PSMA-617 alone for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A real-world prostate cancer disease observation (PRECISION) data platform analysis.
78 Background: 177 Lu-PSMA-617 is currently under investigation in combination with an ARPI in those w...
Phase 1 dose escalation and expansion of AB001 in patients with metastatic castration resistant prostate cancer (mCRPC): The ARTISAN trial.
TPS289 Background: Treatment options for patients with mCRPC have been improved by radioligand therapies such as beta-emit...
Outcomes of radium-223 therapy in combination with enzalutamide for metastatic castration-resistant prostate cancer: A multicenter retrospective analysis in Japan.
66 Background: The PEACE-3 trial demonstrated improved radiographic progression-free survival (rPFS) with radium-223 (Ra-2...
Bridging global gaps: Expanding GU oncology education through iECHO telementoring.
592 Background: As treatments within genitourinary (GU) oncology become increasingly complex, new educational methods are...
Guarding the kidneys in the immunotherapy era: Pooled incidence and severity of immune-related nephritis in renal-cell carcinoma treated with PD-1/PD-L1–based regimens.
489 Background: Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 have redefined renal-cell carcinoma...
Prognostic value of baseline serum IgG in metastatic clear cell renal cell carcinoma treated with first-line IO–TKI therapy.
563 Background: Serum immunoglobulins (IgG, IgA, and IgM) may reflect systemic immune status and potentially influence the...
Four-year outcomes of a genetic-based screening protocol for prostate cancer: Unveiling the Italian paradox.
323 Background: A positive family history is a well-established risk factor for prostate cancer (PCa), making the identifi...
Genomic risk classifier performance in PET-guided post-prostatectomy patients: Secondary analysis of a randomized trial.
386 Background: Genomic risk assessment with genomic classifiers (GC) have enhanced risk stratification in post-prostatect...
Implementing comprehensive population-wide genomic testing in metastatic prostate cancer (mPCa): A real-world Canadian cohort study.
90 Background: Germline and somatic alterations in genes associated with DNA repair are common in patients with mPCa and h...
Preoperative muscle quantity to predict acute kidney injury after radical cystectomy: A multicenter retrospective study.
723 Background: Acute kidney injury (AKI) is a common complication in patients undergoing radical cystectomy (RC), yet its...
CT- vs 1.5T MR-guidance in salvage radiotherapy of locally recurrent prostate cancer after radical prostatectomy.
368 Background: This study compares the treatment outcomes of megavoltage CT-guided RT (CTgRT) and 1.5T MR-guided RT (MRgR...
A provocative analysis of first-line strategies in advanced urothelial carcinoma: Reconstructed individual patient data comparisons of EV–pembrolizumab, avelumab maintenance, and nivolumab–cisplatin–gemcitabine from their pivotal phase 3 trials.
751 Background: The treatment of advanced urothelial carcinoma has been revolutionized by immune checkpoint inhibitors and...
Aligning goals of care at the time of treatment planning with the ABC123 framework: A pilot study.
726 Background: Older patients with incurable genitourinary (GU) cancers are at high risk for receiving care that does not...
A multicohort phase 2 trial of androgen deprivation therapy (ADT), docetaxel (DOCE), and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumors and DNA damage repair (DDR) alterations.
183 Background: This multicenter phase 2 investigator-initiated trial evaluated ADT, DOCE, and NIVO in pts with de novo mH...
Integrating circulating tumor DNA (ctDNA) and <i>TP53</i> alteration variant allele frequency (VAF) to predict outcomes in advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV).
815 Background: EV, alone or combined with pembrolizumab (EVP), is a standard of care for patients (pts) with aUC. Markers...
Effect of tumor methionine metabolism via MAT2A on CD8⁺ T-cell exhaustion through SAM-CHOP axis in bladder cancer.
811 Background: Bladder cancer shows high recurrence and limited benefit from immune-checkpoint blockade. Tumor metabolic...
Proliferation- and immune-informed fusion of multiscale image features for bladder cancer prognosis.
802 Background: Predicting bladder cancer outcomes remains challenging due to pronounced tumor heterogeneity, a challenge...
Prevalence of treatment-acquired homozygous losses (homozygous deletions) of <i>PTEN</i> from androgen receptor pathway inhibitors (ARPI) in metastatic prostate cancer.
27 Background: Validated homozygous loss detection is becoming increasingly important in clinical practice, with prostate...
Patient reported outcomes (PRO) and tolerability of capivasertib (capi) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281.
14 Background: An unmet need for targeted treatments exists for pts with PTEN deficient mHSPC. In the Phase 3 CAPItello-28...
CAST-AI: Cystectomy after systemic therapy with ADC and immunotherapy.
TPS892 Background: Enfortumab Vedotin (EV) plus pembrolizumab (Pembro) is now first-line therapy for advanced urothelial c...
Quality of care (QoC) measures among patients with recurrent, papillary-only bacillus Calmette-Guérin (BCG)-experienced high-risk non-muscle invasive bladder cancer (HR-NMIBC).
709 Background: QoC indicators, including those from the American Urologic Association Quality Registry (AQUA) and Nationa...
HCRN GU22-598: Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder.
TPS891 Background: Radical cystectomy is a standard potentially curative treatment for patients with muscle-invasive bladd...